New clinical trials for the treatment of neuroendocrine tumors

E. Bajetta, E. Bichisao, S. Artale, L. Celio, L. Ferrari, M. Di Bartolomeo, N. Zilembo, S. C. Stani, R. Buzzoni

Research output: Contribution to journalArticle

Abstract

In oncology there is an increasing interest in neuroendocrine tumors, whose incidence is generally considered low, although in a recent analysis of 5,468 cases there was an increase in the proportion of pulmonary and gastric carcinoids and a decrease in the appendiceal carcinoids. However carcinoid tumors are indolent and their diagnosis is often difficult to carry out, so the true incidence may be higher. Surgery remains the treatment of choice and it should always be considered in patients with neuroendocrine tumors although a complete cure is difficult to obtain. Cytotoxic chemotherapy is the medical treatment for highly proliferating neuroendocrine tumors, but it has showed a modest benefit. Somatostatin analogues, octreotide and lanreotide are the standard hormonal treatment for neuroendocrine tumors. Recently, two trials on lanreotide and octreotide have been published, and it is worth noting that in each trial a long-acting formulation has been used: for lanreotide a prolonged-release formulation (PR) which allows an injection of 30 mg every 2 weeks, and for octreotide a long-acting release formulation (LAR) which allows an injection of 10, 20 or 30 mg every 28 days. The results of each trial are very promising. However, there are methodological and clinical aspects which make it difficult to carry out new trials for studying neuroendocrine tumors. The increasing number of biological markers deserve further investigations before their wide use in clinical practice.

Original languageEnglish
Pages (from-to)96-101
Number of pages6
JournalQuarterly Journal of Nuclear Medicine
Volume44
Issue number1
Publication statusPublished - 2000

Fingerprint

Neuroendocrine Tumors
Clinical Trials
Octreotide
Carcinoid Tumor
Therapeutics
Injections
Incidence
Somatostatin
Stomach
Biomarkers
Drug Therapy
Lung
lanreotide

Keywords

  • Carcinoid tumor
  • Clinical trials
  • Neuroendocrine tumors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Bajetta, E., Bichisao, E., Artale, S., Celio, L., Ferrari, L., Di Bartolomeo, M., ... Buzzoni, R. (2000). New clinical trials for the treatment of neuroendocrine tumors. Quarterly Journal of Nuclear Medicine, 44(1), 96-101.

New clinical trials for the treatment of neuroendocrine tumors. / Bajetta, E.; Bichisao, E.; Artale, S.; Celio, L.; Ferrari, L.; Di Bartolomeo, M.; Zilembo, N.; Stani, S. C.; Buzzoni, R.

In: Quarterly Journal of Nuclear Medicine, Vol. 44, No. 1, 2000, p. 96-101.

Research output: Contribution to journalArticle

Bajetta, E, Bichisao, E, Artale, S, Celio, L, Ferrari, L, Di Bartolomeo, M, Zilembo, N, Stani, SC & Buzzoni, R 2000, 'New clinical trials for the treatment of neuroendocrine tumors', Quarterly Journal of Nuclear Medicine, vol. 44, no. 1, pp. 96-101.
Bajetta, E. ; Bichisao, E. ; Artale, S. ; Celio, L. ; Ferrari, L. ; Di Bartolomeo, M. ; Zilembo, N. ; Stani, S. C. ; Buzzoni, R. / New clinical trials for the treatment of neuroendocrine tumors. In: Quarterly Journal of Nuclear Medicine. 2000 ; Vol. 44, No. 1. pp. 96-101.
@article{a45e799c28334730b7c7373d783febf5,
title = "New clinical trials for the treatment of neuroendocrine tumors",
abstract = "In oncology there is an increasing interest in neuroendocrine tumors, whose incidence is generally considered low, although in a recent analysis of 5,468 cases there was an increase in the proportion of pulmonary and gastric carcinoids and a decrease in the appendiceal carcinoids. However carcinoid tumors are indolent and their diagnosis is often difficult to carry out, so the true incidence may be higher. Surgery remains the treatment of choice and it should always be considered in patients with neuroendocrine tumors although a complete cure is difficult to obtain. Cytotoxic chemotherapy is the medical treatment for highly proliferating neuroendocrine tumors, but it has showed a modest benefit. Somatostatin analogues, octreotide and lanreotide are the standard hormonal treatment for neuroendocrine tumors. Recently, two trials on lanreotide and octreotide have been published, and it is worth noting that in each trial a long-acting formulation has been used: for lanreotide a prolonged-release formulation (PR) which allows an injection of 30 mg every 2 weeks, and for octreotide a long-acting release formulation (LAR) which allows an injection of 10, 20 or 30 mg every 28 days. The results of each trial are very promising. However, there are methodological and clinical aspects which make it difficult to carry out new trials for studying neuroendocrine tumors. The increasing number of biological markers deserve further investigations before their wide use in clinical practice.",
keywords = "Carcinoid tumor, Clinical trials, Neuroendocrine tumors",
author = "E. Bajetta and E. Bichisao and S. Artale and L. Celio and L. Ferrari and {Di Bartolomeo}, M. and N. Zilembo and Stani, {S. C.} and R. Buzzoni",
year = "2000",
language = "English",
volume = "44",
pages = "96--101",
journal = "Journal of Nuclear Medicine and Allied Sciences",
issn = "1124-3937",
publisher = "Minerva Medica",
number = "1",

}

TY - JOUR

T1 - New clinical trials for the treatment of neuroendocrine tumors

AU - Bajetta, E.

AU - Bichisao, E.

AU - Artale, S.

AU - Celio, L.

AU - Ferrari, L.

AU - Di Bartolomeo, M.

AU - Zilembo, N.

AU - Stani, S. C.

AU - Buzzoni, R.

PY - 2000

Y1 - 2000

N2 - In oncology there is an increasing interest in neuroendocrine tumors, whose incidence is generally considered low, although in a recent analysis of 5,468 cases there was an increase in the proportion of pulmonary and gastric carcinoids and a decrease in the appendiceal carcinoids. However carcinoid tumors are indolent and their diagnosis is often difficult to carry out, so the true incidence may be higher. Surgery remains the treatment of choice and it should always be considered in patients with neuroendocrine tumors although a complete cure is difficult to obtain. Cytotoxic chemotherapy is the medical treatment for highly proliferating neuroendocrine tumors, but it has showed a modest benefit. Somatostatin analogues, octreotide and lanreotide are the standard hormonal treatment for neuroendocrine tumors. Recently, two trials on lanreotide and octreotide have been published, and it is worth noting that in each trial a long-acting formulation has been used: for lanreotide a prolonged-release formulation (PR) which allows an injection of 30 mg every 2 weeks, and for octreotide a long-acting release formulation (LAR) which allows an injection of 10, 20 or 30 mg every 28 days. The results of each trial are very promising. However, there are methodological and clinical aspects which make it difficult to carry out new trials for studying neuroendocrine tumors. The increasing number of biological markers deserve further investigations before their wide use in clinical practice.

AB - In oncology there is an increasing interest in neuroendocrine tumors, whose incidence is generally considered low, although in a recent analysis of 5,468 cases there was an increase in the proportion of pulmonary and gastric carcinoids and a decrease in the appendiceal carcinoids. However carcinoid tumors are indolent and their diagnosis is often difficult to carry out, so the true incidence may be higher. Surgery remains the treatment of choice and it should always be considered in patients with neuroendocrine tumors although a complete cure is difficult to obtain. Cytotoxic chemotherapy is the medical treatment for highly proliferating neuroendocrine tumors, but it has showed a modest benefit. Somatostatin analogues, octreotide and lanreotide are the standard hormonal treatment for neuroendocrine tumors. Recently, two trials on lanreotide and octreotide have been published, and it is worth noting that in each trial a long-acting formulation has been used: for lanreotide a prolonged-release formulation (PR) which allows an injection of 30 mg every 2 weeks, and for octreotide a long-acting release formulation (LAR) which allows an injection of 10, 20 or 30 mg every 28 days. The results of each trial are very promising. However, there are methodological and clinical aspects which make it difficult to carry out new trials for studying neuroendocrine tumors. The increasing number of biological markers deserve further investigations before their wide use in clinical practice.

KW - Carcinoid tumor

KW - Clinical trials

KW - Neuroendocrine tumors

UR - http://www.scopus.com/inward/record.url?scp=0034115233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034115233&partnerID=8YFLogxK

M3 - Article

C2 - 10932606

AN - SCOPUS:0034115233

VL - 44

SP - 96

EP - 101

JO - Journal of Nuclear Medicine and Allied Sciences

JF - Journal of Nuclear Medicine and Allied Sciences

SN - 1124-3937

IS - 1

ER -